Novartis | NOVN - Operating Profit

Stock Price
119.28
Daily Change
0.58 0.49%
Monthly
6.96%
Yearly
22.08%
Q1 Forecast
111.83

Novartis reported $4.5B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alcon AG USD 332M 85M Sep/2025
Almirall EUR 43.02M 28.78M Jun/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Autolus Therapeutics Ltd USD -82.61M 17.37M Jun/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Fresenius EUR 574M 14M Sep/2025
Fresenius Medical Care EUR 449.94M 18.94M Sep/2025
Galapagos EUR -41.67M 15.36M Sep/2025
Genmab DKK 360M 172M Jun/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GRIFOLS EUR 352.11M 2.57M Sep/2025
Hikma Pharmaceutical USD 187M 95M Jun/2025
J&J USD 5.59B 1.81B Dec/2025
Lonza CHF 430M 104M Dec/2024
Merck EUR 1.21B 180M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Orion EUR 121M 16.4M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Philips EUR 329M 159M Sep/2025
Recordati EUR 165.64M 15.69M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1B 678M Dec/2024